Table 3 Factors associated with % changes in eGFR after starting xanthine oxidase inhibitors

			Multivariate
	Unadjusted		Model 1 (R²=0.17, P=0.04)		Model 2 (R²=0.25, P=0.001)
Variable	β	P-value	β	P-value	β	P-value
Age, years	−0.06	0.47	−0.07	0.50	−0.09	0.34
Sex, female	−0.04	0.66	−0.02	0.86	−0.08	0.4
Diabetes mellitus	0.08	0.38	0.05	0.44	0.05	0.57
Gout	0.14	0.15	0.04	0.73	0.06	0.96
Renin–angiotensin inhibitors	−0.14	0.10	−0.27	0.006	−0.27	0.004
Diuretics	−0.16	0.10	−0.1	0.33	−0.07	0.94
Febuxostat	0.15	0.09	0.18	0.17	0.20	0.07
eGFR at just before Tx, ml min⁻¹ per 1.73 m²	−0.1	0.23	−0.13	0.22	−0.15	0.12
Uric acid at just before Tx, mg dl⁻¹	0.1	0.23	0.07	0.45
Systolic blood pressure at just before Tx, mm Hg	0.05	0.53	−0.04	0.69
Change in uric acid, after Tx, %	−0.23	0.008			−0.24	0.01
Change in systolic blood pressure, after Tx, %	0.12	0.18			0.21	0.03

Abbreviations: eGFR, estimated glomerular filtration rate; Tx, treatment.
Multivariate regression analysis including the following explanatory variables using significant factors in nonadjusted model (P<0.2) in addition to gender and eGFR.
Model 1: gender, eGFR (continuous)+basal significant variable including systolic blood pressure (SBP) (continuous), basal uric acid(continuous) and diuretics.
Model 2: gender, eGFR (continuous)+significant % change in variables including % change in diastolic blood pressure (DBP) and % change in uric acid+diuretics.

Quick links

Search